Pinilla-Ibarz et al listed criteria for clinical intolerance to tyrosin kinase inhibitor therapy. These criteria can be extended to other medications. The authors are from the H. Lee Moffitt Cancer Center in Tampa, Florida.
Criteria for medication intolerance:
(1) sufficient severity and duration
(2) not explained by another cause
(3) not responsive to dose reduction or optimal supportive care
Severity of Adverse Effect
Duration
Grade 4 (severe)
> 7 days
Grade 3
Grade 2 (moderate)
> 1 month
Grade 2 (moderate)
recurrent (>= 4 times)
Grade 1 (mild) and bothersome to the patient
long term
where:
• The original criteria distinguish hematologic from nonhematologic toxicity but these are combined here.
• The duration for Grade 3 toxicity was not specified but > 2 weeks will be used.
To read more or access our algorithms and calculators, please log in or register.
